BSE filing, NSE: VINEETLAB. Summary written from the filing by ALFA Finder's alert engine.
Vineet Laboratories Ltd: key numbers
- Share price
- ₹36.99
- Market cap
- ₹71.04 Cr
- Revenue (annual)
- ₹59.40 Cr
- Net profit (annual)
- ₹1.11 Cr
- P/E (TTM)
- 20.4×Sector 46.5×
- Promoter holding
- 5.98%+0.00% QoQ
- FII holding
- 0.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vineet Laboratories Ltd
All →Vineet Laboratories Q1 FY27 Results: Turns Profitable, Net Profit ₹1.5 Cr
Vineet Laboratories Ltd reported revenue from operations of ₹10.4 Cr (+40.5% YoY) and net profit of ₹1.5 Cr for Q1 FY27.
- Key figure
- Net profit ₹1.5 Cr
Vineet Laboratories Board Meeting Date
Vineet Laboratories Limited has scheduled a board meeting on October 26, 2026, to consider and approve standalone financial results for the quarter ended June 30, 2026.
Vineet Laboratories Other Announcement
Vineet Laboratories Ltd has filed its quarterly shareholding pattern as per Regulation 31(1)(b) of SEBI (LODR) Regulations for the quarter ended September 30, 2026.
Vineet Laboratories Management Change
Mr. Vennapusa Premanand Reddy has resigned as a Director of Vineet Laboratories Limited, effective October 14, 2026.
Vineet Laboratories Management Change
Vineet Laboratories Limited announced the resignation of M/s. NSVR & Associates LLP as its statutory auditor, effective September 29, 2026. The company will appoint a successor.
Vineet Laboratories Q4 FY26 Results: Turns Profitable, Net Profit ₹0.7 Cr
Vineet Laboratories Ltd reported revenue from operations of ₹18.9 Cr (+34.0% YoY) and net profit of ₹0.7 Cr for Q4 FY26.
- Key figure
- Net profit ₹0.7 Cr
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.